A Decade of SG&A: AstraZeneca vs. Teva

A Financial Journey from 2014 to 2023

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, AstraZeneca PLC and Teva Pharmaceutical Industries Limited have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca's SG&A expenses have surged by approximately 35% from 2014 to 2023, peaking in 2022. This reflects their aggressive expansion and strategic investments. In contrast, Teva's SG&A expenses have declined by about 31% over the same period, indicating a focus on cost-cutting and operational streamlining.

Strategic Implications

AstraZeneca's rising SG&A expenses suggest a robust growth strategy, potentially leading to increased market share. Meanwhile, Teva's cost reduction could enhance profitability, albeit at the risk of stifling growth. These financial trajectories offer a glimpse into the strategic priorities of these pharmaceutical giants, providing valuable insights for investors and industry analysts alike.